Clinical Trials Logo

Clinical Trial Summary

The goal of the proposed study is to elucidate neurologic and neuropsychological improvements associated with Palynziq-related reduction in plasma Phe levels in individuals with PKU. To this end, investigators will utilize state-of-the-art neuropsychological and multi-modal neuroimaging methods to examine the effects of large Phe level reduction (levels <360 μmol/L for at least 3 consecutive months) on GM and WM brain structures, brain concentrations of Phe, functionality of brain networks, and associated cognitive functioning in a sample of individuals with PKU who are being treated with Palyzniq.


Clinical Trial Description

Past studies have documented PKU-related disruptions in brain phenylalanine (Phe) levels, white matter (WM) and gray matter (GM) brain structures, functional connectivity, and neurocognitive functioning. Additional research suggests that the disruptive effects of excessive blood Phe levels likely contribute to these abnormalities, and treatment aimed at lower Phe levels may lead to significant improvements. Within this context, the primary aim is to test the hypotheses that Palynziq-related reductions in blood Phe levels will be associated with: 1. A decrease in brain Phe levels as measured by magnetic resonance spectroscopy (MRS). 2. A decrease in the extent and severity of WM abnormalities as evidenced by increased mean diffusivity values - a measure of microstructural WM integrity that is derived via diffusion-weighted magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI). 3. Closer-to-normal volumetric measurements for GM structures. Nature of this effect will be dependent on structure. For example, PKU is associated with increased volume in basal ganglia but decreased volume in posterior cortex and cerebellum (Aldridge et al., 2020; Bodner et al., 2012; Christ et al., 2016). 4. An increase in functional connectivity within the brain's functional networks as measured by resting state functional MRI (fMRI). 5. Improved performance on neurocognitive tests of executive function, attention, processing speed, and motor control. To accomplish this aim, a total sample of up to 13 adults with PKU who have previously completed baseline (pre-Palnyziq) neurocognitive and neuroimaging evaluations will be recruited from the two sites (University of Missouri, Boston Children's Hospital). Participants will be reassessed following a significant and prolonged Phe response to Palynziq (as reflected by at least 3 consecutive months of Phe levels below 360 μmol/L). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05356377
Study type Observational
Source University of Missouri-Columbia
Contact
Status Enrolling by invitation
Phase
Start date May 25, 2022
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05998109 - PheCheck Feasibility Study
Not yet recruiting NCT04433728 - Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
Completed NCT01209819 - Bone Mineral Density in Adults With Hyperphenylalaninemia N/A
Active, not recruiting NCT05174559 - Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU) N/A
Not yet recruiting NCT04969809 - Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients N/A
Recruiting NCT04404530 - Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Recruiting NCT05827536 - Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU. N/A
Active, not recruiting NCT05971563 - Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT04368624 - PKU Skin Stripping
Completed NCT04452513 - A Prospective Clinical Study of Phenylketonuria (PKU)
Completed NCT05497050 - The Effect of Nursing Empowerment Program N/A
Completed NCT04943393 - Remote Neurocognitive and Psychological Assessment in PKU
Completed NCT05096988 - Evaluation of PKU Sphere Liquid N/A
Not yet recruiting NCT06332807 - AAV Gene Therapy Clinical Study in Adult Classic PKU Phase 1/Phase 2
Completed NCT00225615 - A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels Phase 3
Recruiting NCT05128149 - Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Terminated NCT05229549 - Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria N/A
Not yet recruiting NCT06337864 - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria N/A
Completed NCT02445521 - Testing of Four Home Phenylalanine Monitoring Prototype Devices N/A